AKT1 and gastric cancer: The randomized, double-blind, placebo-controlled, multicenter, phase II trial conducted by Bang and colleagues included 153 patients with locally advanced or metastatic GC or gastroesophageal junction cancer who were randomly assigned to receive ipatasertib (AKT inhibitor) or a placebo, plus mFOLFOX6 (1:1).